A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03765-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Niraj Shrestha und 25 weiteren Autor:innen. Beteiligte Einrichtung: HCW Biologics Inc., 2929 N. Commerce Parkway, Miramar, FL, 33025, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, Recombinant Fusion Proteins, Immunologic Memory. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, HCW Biologics.
Abstract (Originalsprache)
Adoptive cellular therapy (ACT) using memory-like (ML) natural killer (NK) cells, generated through overnight ex vivo activation with IL-12, IL-15, and IL-18, has shown promise for treating hematologic malignancies. We recently reported that a multifunctional fusion molecule, HCW9201, comprising IL-12, IL-15, and IL-18 domains could replace individual cytokines for priming human ML NK cell programming (“Prime” step). However, this approach does not include ex vivo expansion, thereby limiting the ability to test different doses and schedules. Here, we report the design and generation of a multifunctional fusion molecule, HCW9206, consisting of human IL-7, IL-15, and IL-21 cytokines. We observed > 300-fold expansion for HCW9201-primed human NK cells cultured for 14 days with HCW9206 and HCW9101, an IgG1 antibody, recognizing the scaffold domain of HCW9206 (“Expand” step). This expansion was dependent on both HCW9206 cytokines and interactions of the IgG1 mAb with CD16 receptors on NK cells. The resulting “Prime and Expand” ML NK cells exhibited elevated metabolic capacity, stable epigenetic IFNG promoter demethylation, enhanced antitumor activity in vitro and in vivo, and superior persistence in NSG mice. Thus, the “Prime and Expand” strategy represents a simple feeder cell-free approach to streamline manufacturing of clinical-grade ML NK cells to support multidose and off-the-shelf ACT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HCW Biologics Inc., 2929 N. Commerce Parkway, Miramar, FL, 33025, USA.
- Wugen, Inc., Saint Louis, MO, 63108, USA.
- Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
- HCW Biologics Inc., 2929 N. Commerce Parkway, Miramar, FL, 33025, USA. hingwong@hcwbiologics.com.
Förderung
- NCI NIH HHS
- NIH HHS
- HCW Biologics
- Wugen
- NIH
- Paula C and Rodger O. Riney Blood Cancer Initiative
Zitieren
APA
Shrestha, N., Dee, M. J., Chaturvedi, P., Leclerc, G. M., Mathyer, M., Dufour, C., Arthur, L., Becker-Hapak, M., Foster, M., McClain, E., Pena, N. V., Kage, K., Zhu, X., George, V., Liu, B., Egan, J., Echeverri, C., Wang, M., You, L., …, & Wong, H. C. (2024). A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03765-8
Vancouver
Shrestha N, Dee MJ, Chaturvedi P, Leclerc GM, Mathyer M, Dufour C, et al. A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03765-8
BibTeX
@article{Shrestha2024,
author = {Shrestha, Niraj and Dee, Michael J and Chaturvedi, Pallavi and Leclerc, Gilles M and Mathyer, Mary and Dufour, Celeste and Arthur, Laura and Becker-Hapak, Michelle and Foster, Mark and McClain, Ethan and Pena, Natalia Valderrama and Kage, Karen and Zhu, Xiaoyun and George, Varghese and Liu, Bai and Egan, Jack and Echeverri, Christian and Wang, Meng and You, Lijing and Kong, Lin and Li, Liying and Berrien-Elliott, Melissa M and Cooper, Matthew L and Fehniger, Todd A and Rhode, Peter R and Wong, Hing C},
title = {A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03765-8}
}
EUVIMED